Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors

Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors

Background: The standard treatment in postmenopausal women with estrogen- and progesterone-positive localized breast cancer consists of aromatase inhibitors (AROi). The ability of AROi to promote or worsen frailty syndrome over time and the relationship with changes in gonadal hormones concentration...

Full description

Bibliographic Details
Main Authors: Javier García-Sánchez, Mayra Alejandra Mafla-España, María Dolores Torregrosa, Omar Cauli
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Biomedicines
Subjects:
aromatase inhibitors
letrozole
anastrozole
testosterone
gonadotropin
frailty
Online Access:https://www.mdpi.com/2227-9059/10/7/1634

Internet

https://www.mdpi.com/2227-9059/10/7/1634

Similar Items